The biopharmaceutical company Almac Discovery - part of the contract development and manufacturing organisation (CDMO) Almac Group -and Elasmogen, a University of Aberdeen spin-out firm and part of the Deepbridge Life Sciences EIS portfolio, have been awarded a £2m grant from Innovate UK.
The companies applied for the grant to support development of a technology platform for next generation VNAR-based oncology medicines.
To find out more click here.
Elasmogen Ltd is a biologics company that was spun out of the University of Aberdeen and has developed a proprietary ‘soloMER’ platform.
Specifically, the Company’s technology comprises a platform exploiting the power of biologics as drugs in small, simple and stable formats (‘soloMERs’). Specifically, they are small (i.e. 9% of the size of a human antibody) and highly stable proteins, making them ideal for both site-specific delivery and the penetration of solid cancerous tumours.